Daraxonrasib for children with RAS-mutant solid tumors
Treatments studied
Part of Cancer clinical trials.
This study tests a new drug (daraxonrasib) for children with solid tumors that have a RAS mutation and have not responded to standard treatments. The drug targets the mutated RAS protein to slow or stop cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 1 and 17 years old.
- The cancer must be a solid tumor (not in the brain) that has come back or not improved after treatment.
- A test must show a RAS mutation (a specific change in the KRAS, NRAS, or HRAS genes).
- Your child must have recovered from side effects of previous treatments like chemotherapy or radiation.
- Your child must be able to swallow tablets whole.
- Your child must not have had a transplant or certain treatments within specific time frames before starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new pill called Daraxonrasib that targets cancers with a specific KRAS mutation. It is for people with advanced bile duct cancer that has grown after at least one prior treatment, to see if it can shrink the cancer or slow its growth.
This trial tests a new daily pill (daraxonrasib/RMC-6236) for people with advanced non-small cell lung cancer that has a specific RAS mutation. It's for those who have already tried 1 or 2 previous treatments, including immunotherapy and chemotherapy.
This trial tests a new targeted therapy (daraxonrasib) combined with standard chemotherapy as the first treatment for people whose pancreatic cancer has spread. The goal is to see if this combination can help shrink or control the cancer better than chemotherapy alone.
This study tests two oral medicines (elironrasib and daraxonrasib) given alone or together to see if they can shrink tumors or slow down cancer growth in people with advanced solid tumors that have a KRAS G12C mutation. It is for people who have already tried other treatments.
This trial tests new drugs called RAS(ON) inhibitors combined with ivonescimab for people with solid tumors that have a RAS mutation. It aims to see if this combination can shrink tumors or slow their growth.
This trial tests a new drug called RMC-5127 for people with advanced solid tumors that have a specific KRAS G12V mutation. The study aims to see if this targeted therapy can help when other treatments have stopped working or caused side effects.
Hear when a new Recurrent Childhood Malignant Solid Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.